Physician profile
Charles Eil
NPI 1134176886
$8,107.99
in general payments reported to CMS, 2019-2025
36 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $1,107 · 2021: $2,016 · 2022: $1,355 · 2023: $996 · 2024: $607 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $1,012.94 | 2019-2025 | Korlym |
| Amgen INC. | $991.95 | 2019-2025 | Evenity, Tepezza |
| Novo Nordisk INC | $856.26 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $694.31 | 2021-2025 | |
| Medtronic, INC. | $677.02 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $534.66 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.63 | 2019-2022 | |
| Lilly USA, LLC | $515.04 | 2019-2022 | |
| Abbott Laboratories | $445.62 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $404.14 | 2019-2022 | |
| Mannkind Corporation | $161.24 | 2021-2022 | |
| Insulet Corporation | $142.20 | 2019 | |
| Lifescan, INC. | $129.67 | 2019-2021 | |
| Vifor Pharma, INC. | $110.94 | 2019 | |
| Abbvie INC. | $81.81 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $80.05 | 2019 | |
| Beta Bionics, INC. | $73.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $72.50 | 2019-2022 | |
| Radius Health, INC. | $70.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $70.47 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $62.98 | 2019-2022 | |
| Amarin Pharma, INC. | $39.40 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $39.13 | 2021 | |
| Pfizer INC. | $36.72 | 2019 | |
| Medtronic Minimed, INC. | $36.06 | 2019-2020 | |
| Ibsa Pharma INC. | $29.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $26.09 | 2019-2020 | |
| Nevro Corp. | $25.32 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.01 | 2021 | |
| Antares Pharma, INC. | $22.07 | 2019 | |
| Companion Medical, INC. | $21.74 | 2019 | |
| Acerus Pharmaceuticals Corporation | $20.83 | 2020 | |
| Cequr Corporation | $19.75 | 2025 | Cequr Simplicity |
| Amryt Pharma Holdings Ltd | $18.82 | 2022 | |
| Sobi, INC | $15.97 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Eil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.